agmatineWhat was measured
Measured, with no finding
4 endpoints
Show what was measuredHide what was measured
average pain measures, improvement as percent of baseline
decreases, p = 0.05
significantly enhanced improvement in average pain measures and in quality of life scores occurred after treatment in the agmatine group (26.7% and 70.8%, respectively) as compared with placebo (6.0% [P </= 0.05] and 20.0% [P </= 0.05], respectively)
PMID 20447305 · one of two readings recorded this
average pain measures (instrument not named in the results sentence; Methods lists VAS, McGill pain questionnaire, Oswestry disability index)
increases, improvement 26.7% of baseline on agmatine vs 6.0% on placebo
Not recorded as a finding: vas-pain requires the VAS to be named; the sentence says only 'average pain measures', so the instrument cannot be tied to the node (abstract only)
Expressed as percent of baseline values, significantly enhanced improvement in average pain measures and in quality of life scores occurred after treatment in the agmatine group (26.7% and 70.8%, respectively) as compared with placebo (6.0% [P </= 0.05] and 20.0% [P </= 0.05], respectively).
PMID 20447305 · one of two readings recorded this
average pain measures, visual analog scale / McGill pain questionnaire (abstract does not tie the improvement sentence to one instrument)
increases, improvement 26.7% of baseline with agmatine vs 6.0% with placebo
Not recorded as a finding: CAT:outcome/vas-pain is instrument-bound; the results sentence says only 'average pain measures' and does not name VAS, so no mapping onto that node.
Expressed as percent of baseline values, significantly enhanced improvement in average pain measures and in quality of life scores occurred after treatment in the agmatine group (26.7% and 70.8%, respectively) as compared with placebo (6.0% [P </= 0.05] and 20.0% [P </= 0.05], respectively).
PMID 20447305 · one of two readings recorded this
quality of life scores, improvement as percent of baseline
increases, p = 0.05
significantly enhanced improvement in average pain measures and in quality of life scores occurred after treatment in the agmatine group (26.7% and 70.8%, respectively) as compared with placebo (6.0% [P </= 0.05] and 20.0% [P </= 0.05], respectively)
PMID 20447305 · one of two readings recorded this